Jump to main content
Jump to site search


What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks

Author affiliations

Abstract

In light of the Covid-19 outbreak, this review brings together historical and current literature efforts towards the development of antiviral metallodrugs. Classical compounds such as CTC-96 and auranofin are discussed in depth, as pillars for future metallodrug development. From the recent literature, both cell-based results and biophysical assays against potential viral biomolecule targets are summarized here. The comprehension of the biomolecular targets and their interactions with coordination compounds are emphasized as fundamental strategies that will foment further development of metal-based antivirals. We also discuss other possible and unexplored methods for unveiling metallodrug interactions with biomolecules related to viral replication and highlight the specific challenges involved in the development of antiviral metallodrugs.

Graphical abstract: What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks

Back to tab navigation

Article information


Submitted
14 Jul 2020
Accepted
31 Aug 2020
First published
03 Sep 2020

Dalton Trans., 2020, Advance Article
Article type
Perspective

What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks

R. E. F. de Paiva, A. Marçal Neto, I. A. Santos, A. C. G. Jardim, P. P. Corbi and F. R. G. Bergamini, Dalton Trans., 2020, Advance Article , DOI: 10.1039/D0DT02478C

Social activity

Search articles by author

Spotlight

Advertisements